Amelioration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced behavioural dysfunction and oxidative stress by Pycnogenol in mouse model of Parkinson's disease

Behavioural Pharmacology

Volumn 21, Issue 5-6, 2010, Pages 563-571

  Khan, Mohammad Moshahid ^a   Hoda, Md Nasrul ^a   Ishrat, Tauheed ^a   Ahmad, Ajmal ^a   Khan, Mohammad Badruzzaman ^a   Khuwaja, Gulrana ^a   Raza, Syed Shadab ^a   Safhi, Mohammed M ^a   Islam, Fakhrul ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Antioxidant enzymes; free radicals; MPTP; Parkinsonism; Pycnogenol

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; CATALASE; DOPAMINE; DOPAMINE 2 RECEPTOR; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; PYCNOGENOL; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIOCHEMISTRY; CONTROLLED STUDY; CORPUS STRIATUM; DETERIORATION; ENZYME ACTIVITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; TREATMENT DURATION;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DOPAMINE; FLAVONOIDS; GLUTATHIONE; MICE; MPTP POISONING; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PINUS; PLANT EXTRACTS; RECEPTORS, DOPAMINE D2; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 77955985008     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833d4186     Document Type: Article

References (49)

1. Agrawal AK, Hussin R, Raghubir R, Kumar A, Seth PK (1995). Neuro-behavioral, neurochemical and electrophysiological studies in 6-hydroxydo-pamine lesioned and neural transplanted rats. Int J Dev Neurosci 13:105-111.
2. Ahmad AS, Ansari MA, Ahmad M, Saleem S, Yousuf S, Hoda MN, Islam F (2005). Neuroprotection by crocetin in a hemi-parkinsonian rat model. Pharmacol Biochem Behav 81:805-813.
3. Ahmad M, Yousuf S, Khan MB, Ahmad AS, Saleem S, Hoda MN, Islam F (2006). Protective effects of ethanolic extract of Delphinium denudatum in a rat model of Parkinson's disease. Hum Exp Toxicol 25:361-368.
4. Ansari MA, Keller JN, Scheff SW (2008). Protective effect of Pycnogenol in human neuroblastoma SH-SY5Y cells following acrolein-induced cytotoxicity. Free Radic Biol Med 45:1510-1519.
5. Avrova NF, Victorov IV, Tyurin VA, Zakharova IO, Sokolova TV, Andreeva NA, et al. (1998). Inhibition of glutamate-induced intensification of free radical reactions by gangliosides: possible role in their protective effect in rat cerebellar granule cells and brain synaptosomes. Neurochem Res 23:945-952.
6. Bavaresco CS, Calcagnotto T, Tagliari B, Delwing D, Lamers ML, Wannmacher CM, et al. (2003). Brain Na +,K(+)-ATPase inhibition induced by arginine administration is prevented by vitamins E and C. Neurochem Res 28:825-829.
7. Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA (1994). Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 668:261-265.
8. Bito T, Roy S, Sen CK, Packer L (2000). Pine bark extract pycnogenol downregulates IFN-gamma-induced adhesion of T cells to human keratinocytes by inhibiting inducible ICAM-1 expression. Free Radic Biol Med 28:219-227.
9. Bizzozero OA, Reyes S, Ziegler J, Smerjac S (2007). Lipid peroxidation scavengers prevent the carbonylation of cytoskeletal brain proteins induced by glutathione depletion. Neurochem Res 32:2114-2122.
10. Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG (2008). Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 32:1243-1250.
11. Burns RN, Chiueh DD, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983). A primate model of parkinsonism: selective destruction of dopa-minergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci\USA 80:4546-4550.
12. Caliborne A (1985). Catalase activity. In: Greenwald RA, editor. Handbook of methods for oxygen radical research. Boca Raton, FL: CRC; pp. 283-284.
13. Carlberg I, Mannervik B (1975). Glutathione reductase levels in rat brain. J Biol Chem 250:5475-5480.
14. Clark J, Simon DK (2009). Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 11:1-20.
15. DeVito MJ, Wagner GC (1989). Methamphemtamine induced neuronal damage: a possible role for free radicals. Neuropharmacol 28:1145-1150.
16. Drehsen G (1999). From ancient pine bark uses to Pycnogenol. In: Packer L, Miramatzu M, Yoshikawa T, editors. Antioxidant food supplements in human health. New York: Academic Press; pp. 311-322.
17. Habig WH, Pabst MJ, Jokoby WB (1974). Glutathion-S-transferase: the first enzymetic step in mercapturic acid formation. J Biol Chem 249:7130-7139.
18. Halliwell B, Gutteridge J, Cross CE (1992). Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 119:598-620.
19. Hu XT, Watchel SR, Gallowy MP, White FJ (1990). Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonist on caudate putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J Neurosci 10:2318-2329.
20. Ishrat T, Parveen K, Hoda MN, Khan MB, Yousuf S, Ansari MA, et al. (2009). Effects of Pycnogenol and vitamin E on cognitive deficits and oxidative damage induced by intracerebroventricular streptozotocin in rats. Behav Pharmacol 20:567-575.
21. Islam F, Zia S, Sayeed I, Kaur P, Ahmad AS (2004). Effect of selenium on lipids, lipid peroxidation, and sulfhydryl group in neuroendocrine centers of rats. Biol Trace Elem Res 97:1-81.
22. Jankyova S, Kucera P, Goldenberg Z, Yaghi D, Navarova J, Kyselova Z, et al. (2009). Pycnogenol efficiency on glycaemia, motor nerve conduction velocity and markers of oxidative stress in mild type diabetes in rats. Phytother Res 23:1169-1174.
23. Jenner P (2008). Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64:16-29.
24. Jollow DJ, Mitchell JR, Zampagloine N, Gillete JR (1974). Bromobenzene-induced liver necrosis: protective role of glutathione and evidence for 3, 4 bromobenze-neoxide as the hepatotoxic intermediate. Pharmacology 11:151-169.
25. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhartk S, Zhang G, et al. (1998). Locomotor activity in D2 dopamine receptor deficient mice in determined by gene dosage, genetic background and developmental adaptations. Neurosci 18:7470-7479.
26. Lowry OH, Rosenbrough NJ, Far AL, Randall RJ (1951). Protein measurement with Folin phenol reagent. J Biol Chem 193:265-275.
27. Maritim A, Dene BA, Sanders RA, Watkins JB (2003). Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats. J Biochem Mol Toxico 17:193-199.
28. Mohanasundari M, Srinivasan MS, Sethupathy S, Sabesan M (2006). Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J Neurol Sci 249:140-144.
29. Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller D (1984). Differential distribution of glutathione and glutathione related enzymes in rabbit kidneys: possible implication in analgesic neuropathy. Cancer Res 44:5086-5091.
30. Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, et al. (2009). Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro- pyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 15:332-347.
31. Packer L, Rimbach G, Virgili F (1999). Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 27:704-724.
32. Peng Q, Wei Z, Lau BH (2000). Pynogenol inhibits tumor necrosis factor-alpha induces nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 57:834-841.
33. Pietta PG (2000). Flavonoids as antioxidants. J Nat Prod 63:1035-1042.
34. Rajeswari A, Sabesan M (2008). Neuropathological changes induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in male Swiss albino mice. Toxicol Ind Health 3:189-194.
35. Roghani M, Behzadi G (2001). Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res 892:211-217.
36. Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO (2008). EGb761 protects against nigrostriatal dopami-nergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced Par-kinsonism in mice: role of oxidative stress. Eur J Neurosci 28:41-50.
37. Ryan J, Croft K, Mori T, Wesnes K, Spong J, Downey L, et al. (2008). An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol 22:553-562.
38. Sánchez-Iglesias S, Rey P, Méndez-Alvarez E, Labandeira-García JL, Soto-Otero R (2007). Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem Res 32:99-105.
39. Schwarting RKW, Hudson JL (1996). The unilateral 6-OHDA injection lesion model in behaviour brain research: analysis of functional deficit, recovery and treatment. Prog Neurobiol 50:275-331.
40. Schwarting RKW, Bonatz AE, Carey JP, Hudson JL (1991). Relationship between indices of behaviour asymmetries and neurochemical changes following mesencephalic 6-OHDA injections. Brain Res 554:46-56.
41. Stevens M, Obrosova I, Cao X, Huysen CV, Green DA (2000). Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006-1015.
42. Sun Y (1990). Free radicals, antioxidant enzymes and carcinogenesis. Free Rad Biol Med 8:583-599.
43. Tillerson JL, Michael Caudle W, Reverson ME, Miller GW (2002). Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 178:80-90.
44. Turski L, Bressler K, Rettig KJ, Loschmann PA, Watchel H (1991). Protection of substantia nigra from MPTP neurotoxicity by N-methyl-D-aspartate atago-nists. Nature 349:414-418.
45. Utley HC, Bernheim F, Hochslein P (1967). Effect of sulfahydryl reagent on peroxidation in microsome. Arch Biochem Biophys 260:521-531.
46. Yang YS, Ahn TH, Lee JC, Moon CJ, Kim SH, Jun W, et al. (2008). Protective effects of Pycnogenol on carbon tetrachloride-induced hepatotoxicity in Sprague-Dawley rats. Food Chem Toxicol 46:380-387.
47. Yokoyama H, Kuroiwa H, Yano R, Araki T (2008). Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 29:293-301.
48. Zafar KS, Siddiqui A, Sayeed I, Ahmad M, Salim S, Islam F (2003). Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Neurochem 84:438-446.
49. Zhou C, Huang Y, Przedborskia S (2008). Oxidative stress in Parkinson's disease a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 1147:93-104.